In San Francisco for #GUCS24 - join Benjamin L Maughan and me in the Marquis lobby tomorrow at 6 am for a fun run before an exciting first day ASCO Sumanta K. Pal, MD, FASCO Toni Choueiri, MD

Excited build upon the success of DAD now featured in Annals of Oncology and highlighted in excellent talk by Sumanta K. Pal, MD, FASCO DAD-IO opening soon with Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD Guru P. Sonpavde, MD joaquim bellmunt Dana-Farber

Had a great run yesterday so let’s do it again before we finish up an exciting #GU24 ASCO Meet in Marquis lobby at 6 am! Benjamin L Maughan Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Omar Alhalabi, MD

Pembrolizumab already shown to improve DFS improves overall survival in adjuvant setting for high risk localized disease and M1NED with 38% reduction in risk of death Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

Excellent discussion by Pedro C Barata, MD MSc FACP placing KN564 data in context - a win for our patients! Looking forward to ongoing trials and building on success with STRIKE - pembro with or without tivozanib for high risk resected localized RCC Alliance for Clinical Trials in Oncology Dana-Farber Lank Center for Genitourinary Oncology Stephanie Berg

Bradley McGregor Pedro C Barata, MD MSc FACP Alliance for Clinical Trials in Oncology Dana-Farber Lank Center for Genitourinary Oncology A032201/STRIKE in development and will be an important addition to KN-564 esp for those with early progression (IMP) AVEO Oncology Alliance for Clinical Trials in Oncology NCI Center for Cancer Research #GU24

An AM run was a great way to start the final day of #GU24 ASCO with Benjamin L Maughan Omar Alhalabi, MD Hyung Kim Michael Palliola Naomi Haas - looking forward to a run at the best conference! Maybe Sumanta K. Pal, MD, FASCO or Toni Choueiri, MD will join!

Great to see ⁦Neelima Denduluri⁩ ⁦Suzanne Cole, MD⁩ at #GU24 ⁦ASCO⁩ LDP mini reunion!

Ran into ⁦⁦Sumanta K. Pal, MD, FASCO⁩ for a larger reunion! ⁦ASCO⁩ LDP was a great experience and great to catch up! ⁦Neelima Denduluri⁩ ⁦Suzanne Cole, MD⁩

I signed ASCO’s letter from America’s cancer doctors & providers urging policymakers to end the drug shortage crisis. Patients are still struggling to get the treatments they need. Add your voice to the push for solutions & sign the letter! #ASCOAdvocacy asco.quorum.us/campaign/56411…

DADIO is happening! Building upon success of EV and SG adding pembro - learn more at poster board 307A - TPS4618 ASCO Toni Choueiri, MD joaquim bellmunt Dana-Farber Lank Center for Genitourinary Oncology Guru P. Sonpavde, MD

A great way to start day 3 at #ASCO24 - beautiful 6+ mile run with Benjamin L Maughan Missing Sumanta K. Pal, MD, FASCO

Anyone up for a run at #WorldGU24? Too hard to pass up a run around Central Park as a warmup for Pan-Mass Challenge this weekend! Anyone interested let’s meet in JW lobby at 515

930 am and already over 40 miles in to Pan-Mass Challenge with Toni Choueiri, MD Michael Serzan, MD profile.pmc.org/BM0366

87 miles down all before 1 pm for Pan-Mass Challenge Looking forward to day 2 tomorrow with Michael Serzan, MD and Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology profile.pmc.org/BM0366

60 miles before 9 am l Pan-Mass Challenge with Michael Serzan, MD Toni Choueiri, MD 20 to go!

Getting ready for the WEEI Dana-Farber telethon to raise money for cancer research! #KCANCER

First presentation of ESMO - Eur. Oncology - addition of nivoluamb to tiovzanib does not improve outcomes following progression on immunotherapy; tivozanib with encouraging PFS of over 9 months when used second line - full data in The Lancet Toni Choueiri, MD Aly-Khan Lalani Dana-Farber Lank Center for Genitourinary Oncology

Nivo/ipi improves 12 month overall survival rate vs SOC with ORR 33%; responses seen in 7 patients (25% ORR) with chromophobe RCC. PDL1 may be a predictive biomarker #ESMO2024 Toni Choueiri, MD Aly-Khan Lalani

NKT2152 an oral hf2 inhibitor with half life of 38 days has activity in heavily treated ccRCC with ORR 20% (26% with longer followup) with no unexpected toxicity. Trials ongoing exploring dose and activity following belzutifan - open Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD